Photobiomodulation Therapy on the Treatment of Insulin Resistance: A Narrative Review

Magalhães, Flávio de Castro; Ferraresi, Cleber

doi:10.1089/photob.2022.0031

Cited by 8 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Animal [33, 34], as well as cell culture [30–32] studies have provided evidence that PBMt can improve insulin signaling by activating the Akt‐AS160‐GLUT4 pathway, and thus increasing glucose uptake and glycogen synthesis [53]. In a recent review, we summarized some possible mechanisms of PBMt‐induced improvement in glucose metabolism [45]. Therefore, we believe it is reasonable to suggest that similar mechanisms would occur in the present study.…”

Section: Discussionsupporting

confidence: 62%

“…As there is evidence that the combination of oral hypoglycemic medications with other hypoglycemic approaches, such as physical exercise, oftentimes produces counterintuitive results [41][42][43][44], it is of great importance to investigate the combined effects of PBMt and these commonly prescribed drugs on glycemia in T2DM patients. Thus, clinical studies on the combination of PBMt plus oral hypoglycemic medications are lacking and urgently needed [45].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dose and time–response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double‐blind, sham‐controlled trial

Scontri,

de Castro Magalhães,

Damiani

et al. 2023

Journal of Biophotonics

Self Cite

View full text Add to dashboard Cite

Photobiomodulation therapy (PBMt) combined or not with oral hypoglycemic medication has not been investigated in type 2 diabetes (T2DM) patients. All 10 T2DM patients were assessed randomly at 6 different occasions (3 with and 3 without regular oral hypoglycemic medication). Capillary glycemia was assessed after overnight fast (pre‐prandial), 1 h postprandially (standardized meal, 338 kcal), and 30 min, 3 h, 6 h, 12 h post‐PBMt (830 nm; 25 arrays of LEDs, 80 mW/array). Three doses (0 J—sham, 100 J, 240 J per site) were applied bilaterally on quadriceps femoris muscles, hamstrings, triceps surae, ventral upper arm and forearm; and randomly combined or not with oral hypoglicemic medication, totaling six different therapies applied for all 10 TDM2 patients (PBMt sham, PBMt 100 J, PBMt 240 J, PBMt sham + medication, PBMt 100 J + medication, PBMt 240 J + medication). Cardiac autonomic control was assessed by heart rate variability (HRV) indices. Without medication, there was reduction in glycemia after all PBMt doses, with 100 J as the best dose that persisted until 12 h and presented lower area under the curve (AUC). With medication, glycemia decreased similarly among doses. No differences between 100 J and sham + medication, but AUC was significantly lower after 100 J, suggesting better glycemic control. Low frequency component of HRV increased after sham + medication and 100 J, suggesting higher sympathetic activation. PBMt showed time– and dose–response effect to reduce glycemia in T2DM patients. Effects on HRV were consistent with glycemic control.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Dose and time–response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double‐blind, sham‐controlled trial

Scontri,

de Castro Magalhães,

Damiani

et al. 2023

Journal of Biophotonics

Self Cite

View full text Add to dashboard Cite

show abstract

“…No ideal wavelength, including dosimetry or single-point vs. full-body irradiation with LED for external PBM to treat insulin resistance, has been established [ 31 ]. Approximately 600 nm or 800 nm is usually applied for external PBM in animal models [ 7 , 8 , 9 , 10 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

Duodenal Dual-Wavelength Photobiomodulation Improves Hyperglycemia and Hepatic Parameters with Alteration of Gut Microbiome in Type 2 Diabetes Animal Model

Min

Kwon

et al. 2022

Cells

View full text Add to dashboard Cite

Background: Recently, the duodenum has garnered interest for its role in treating metabolic diseases, including type 2 diabetes (T2DM). Multiple sessions of external photobiomodulation (PBM) in previous animal studies suggested it resulted in improved hyperglycemia, glucose intolerance, and insulin resistance with a multifactorial mechanism of action, despite the target organ of PBM not being clearly proven. This study aimed to determine whether a single session of a duodenal light-emitting diode (LED) PBM may impact the T2DM treatment in an animal model. Methods: Goto–Kakizaki rats as T2DM models were subjected to PBM through duodenal lumen irradiation, sham procedure, or control in 1-week pilot (630 nm, 850 nm, or 630/850 nm) and 4-week follow-up (630 nm or 630/850 nm) studies. Oral glucose tolerance tests; serum glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide, and insulin levels; liver chemistry and histology; and gut microbiome in the PBM, sham control, and control groups were evaluated. Results: In the 1-week study, duodenal dual-wavelength (D, 630/850 nm) LED PBM showed improved glucose intolerance, alkaline phosphatase and cholesterol levels, and weight gain than other groups. The D-LED PBM group in the 4-week study also showed improved hyperglycemia and liver enzyme levels, with relatively preserved pancreatic islets and increased serum insulin and GLP-1 levels. Five genera (Bacteroides, Escherichia, Parabacteroides, Allobaculum, and Faecalibaculum) were significantly enriched 1 week after the D-LED PBM. Bacteroides acidifaciens significantly increased, while Lachnospiraceae significantly decreased after 1 week. Conclusion: A single session of D-LED PBM improved hyperglycemia and hepatic parameters through the change of serum insulin, insulin resistance, insulin expression in the pancreatic β-cells, and gut microbiome in T2DM animal models.

show abstract

“…Photobiomodulation, a non-thermal light therapy, has been proposed to restore the balance of gut microbiota. It was found to effectively inhibit mitochondrial dysfunction, reactive oxidative stress, inflammation, and gut dysbiosis in chronic kidney diseases, Alzheimer’s disease, and type 2 diabetes mellitus [ 118 , 119 ].…”

Section: Therapeutic Strategies Target the Intestinal Microenvironmentmentioning

confidence: 99%

Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases

Wang¹,

Zhu²,

Leng³

et al. 2023

Nutrients

View full text Add to dashboard Cite

Gut microbiota is the largest and most complex microflora in the human body, which plays a crucial role in human health and disease. Over the past 20 years, the bidirectional communication between gut microbiota and extra-intestinal organs has been extensively studied. A better comprehension of the alternative mechanisms for physiological and pathophysiological processes could pave the way for health. Cardiovascular disease (CVD) is one of the most common diseases that seriously threatens human health. Although previous studies have shown that cardiovascular diseases, such as heart failure, hypertension, and coronary atherosclerosis, are closely related to gut microbiota, limited understanding of the complex pathogenesis leads to poor effectiveness of clinical treatment. Dysregulation of inflammation always accounts for the damaged gastrointestinal function and deranged interaction with the cardiovascular system. This review focuses on the characteristics of gut microbiota in CVD and the significance of inflammation regulation during the whole process. In addition, strategies to prevent and treat CVD through proper regulation of gut microbiota and its metabolites are also discussed.

show abstract

Photobiomodulation Therapy on the Treatment of Insulin Resistance: A Narrative Review

Cited by 8 publications

References 81 publications

Dose and time–response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double‐blind, sham‐controlled trial

Dose and time–response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double‐blind, sham‐controlled trial

Duodenal Dual-Wavelength Photobiomodulation Improves Hyperglycemia and Hepatic Parameters with Alteration of Gut Microbiome in Type 2 Diabetes Animal Model

Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases

Contact Info

Product

Resources

About